All In MedTech

Device Trial Radar · NCT07939061

Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder

Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder: A Prospective, Randomized, Sham-Controlled Clinical Trial

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

47

Planned (sponsor's estimate)

Start

Sep 3, 2026

Primary completion

Jun 1, 2028

Study completion Jun 1, 2028

Sponsor

Lead sponsor
General University Hospital, PragueAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 16, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 7 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective, randomized, sham-controlled clinical investigation evaluates the efficacy and safety of peroneal transcutaneous electrical neuromodulation (URIS I system) in children aged 7-12 years with wet overactive bladder and daytime urinary incontinence who did not respond or responded insufficiently to standard urotherapy. Participants are randomized 1:1 to active or sham stimulation and receive 12 weekly bilateral sessions of 30 minutes over 12 weeks.

Conditions

  • Overactive Bladder
  • Daytime Urinary Incontinence

Interventions

  • Active peroneal transcutaneous neuromodulation (URIS I, Stimvia)Device

    Bilateral peroneal transcutaneous electrical neuromodulation with the URIS I system. A neutral self-adhesive electrode is placed on the lower abdomen; the optimal stimulation point at the lateral edge of the popliteal fossa is identified by a rhythmic motor response of the leg, and the stimulation voltage is set to the lowest value that evokes this response. Stimulation lasts 30 minutes, once a week for 12 weeks (12 sessions). The device emits a 4 Hz acoustic signal.

  • Sham peroneal transcutaneous neuromodulation (URIS I, Stimvia)Device

    Identical preparation, electrode placement and duration as active stimulation, but the stimulation voltage is set to 0 V bilaterally so that no stimulation is delivered. Exposure to active stimulation is limited to the minimum needed to locate the stimulation point. 30 minutes, once a week for 12 weeks (12 sessions). The device emits the same 4 Hz acoustic signal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of clinical responders at the end of treatmentTime frame: Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • General University Hospital

    Prague, Czechia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.